Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $14.94 down -8.85% from its previous closing price of $16.39. In other words, the price has decreased by -$8.85 from its previous closing price. On the day, 1.77 million shares were traded. KALV stock price reached its highest trading level at $16.4 during the session, while it also had its lowest trading level at $14.8.
Ratios:
For a deeper understanding of KalVista Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.22. In the meantime, Its Debt-to-Equity ratio is 16.62 whereas as Long-Term Debt/Eq ratio is at 16.34.
Upgrades & Downgrades
In the most recent recommendation for this company, Needham on January 09, 2026, Reiterated its Buy rating but revised its target price to $35 from $32 previously.
On January 06, 2026, Needham reiterated its Buy rating and also lowered its target price recommendation from $28 to $32.
On January 31, 2025, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $19.JMP Securities initiated its Mkt Outperform rating on January 31, 2025, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 08 ’25 when Palleiko Benjamin L sold 7,294 shares for $16.51 per share. The transaction valued at 120,424 led to the insider holds 424,520 shares of the business.
Sweeny Nicole sold 3,813 shares of KALV for $51,289 on Nov 24 ’25. The Chief Commercial Officer now owns 39,728 shares after completing the transaction at $13.45 per share. On Nov 24 ’25, another insider, Piekos Brian, who serves as the Chief Financial Officer of the company, sold 4,471 shares for $13.45 each. As a result, the insider received 60,139 and left with 10,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 755161600 and an Enterprise Value of 728582592. For the stock, the TTM Price-to-Sale (P/S) ratio is 528.08 while its Price-to-Book (P/B) ratio in mrq is 44.42. Its current Enterprise Value per Revenue stands at 510.928 whereas that against EBITDA is -3.61.
Stock Price History:
The Beta on a monthly basis for KALV is -0.19, which has changed by 1.0852418 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $19.00, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 3.05%, while the 200-Day Moving Average is calculated to be 13.16%.
Shares Statistics:
For the past three months, KALV has traded an average of 1.34M shares per day and 1575430 over the past ten days. A total of 50.54M shares are outstanding, with a floating share count of 37.84M. Insiders hold about 25.14% of the company’s shares, while institutions hold 97.18% stake in the company. Shares short for KALV as of 1767139200 were 16913184 with a Short Ratio of 12.58, compared to 1764288000 on 14426123. Therefore, it implies a Short% of Shares Outstanding of 16913184 and a Short% of Float of 37.65.
Earnings Estimates
. The current market rating for KalVista Pharmaceuticals Inc (KALV) reflects the collective analysis of 8 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.36 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.65 and -$3.76 for the fiscal current year, implying an average EPS of -$2.94. EPS for the following year is -$2.06, with 9.0 analysts recommending between -$0.36 and -$3.32.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $30.81M. There is a high estimate of $42.6M for the next quarter, whereas the lowest estimate is $15.5M.
Based on 9 analysts’ estimates, the company’s revenue will be $139.45M in the next fiscal year. The high estimate is $246.2M and the low estimate is $49.79M.
